Woiwode Thomas
Insider CIK 1619294 · ADVM Director · TPST Director, 10% owner · BOLD Director · GRTS Director, 10% owner · CRSP Director · PASG Director, 10% owner · ALGS Director
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| PASG Passage BIO, Inc. | A Award deriv | 2023-05-25 | 2023-05-26 | 24,000 | — | $0 | 24,000 | SEC↗ |
| ALGS Aligos Therapeutics, Inc. | A Award deriv | 2022-06-23 | 2022-06-27 | 15,000 | — | $0 | 15,000 | SEC↗ |
| TPST Tempest Therapeutics, Inc. | A Award deriv | 2022-06-17 | 2022-06-22 | 3,500 | — | $0 | 3,500 | SEC↗ |
| PASG Passage BIO, Inc. | A Award deriv | 2022-05-26 | 2022-05-31 | 24,000 | — | $0 | 24,000 | SEC↗ |
| TPST Tempest Therapeutics, Inc. | P Buy | 2022-04-29 | 2022-05-03 | 2,118,644 | $2.36 | $5.00M | 2,118,644 | SEC↗ |
| GRTS Gritstone bio, Inc. | J Other | 2021-08-25 | 2021-08-27 | 6,612 | — | $0 | 6,612 | SEC↗ |
| GRTS Gritstone bio, Inc. | J Other | 2021-08-25 | 2021-08-27 | 444,744 | — | $0 | 902,965 | SEC↗ |
| GRTS Gritstone bio, Inc. | J Other | 2021-08-25 | 2021-08-27 | 128 | — | $0 | 128 | SEC↗ |
| GRTS Gritstone bio, Inc. | J Other | 2021-08-25 | 2021-08-27 | 6,612 | — | $0 | 0 | SEC↗ |
| GRTS Gritstone bio, Inc. | J Other | 2021-08-25 | 2021-08-27 | 6,668 | — | $0 | 0 | SEC↗ |
| GRTS Gritstone bio, Inc. | J Other | 2021-08-25 | 2021-08-27 | 6,668 | — | $0 | 6,668 | SEC↗ |
| TPST Tempest Therapeutics, Inc. | A Award deriv | 2021-07-01 | 2021-07-06 | 6,635 | — | $0 | 6,635 | SEC↗ |
| TPST Tempest Therapeutics, Inc. | A Award deriv | 2021-07-01 | 2021-09-20 | 6,635 | — | $0 | 6,635 | SEC↗ |
| TPST Millendo Therapeutics, Inc | A Award | 2021-06-25 | 2021-06-29 | 997,940 | — | $0 | 997,940 | SEC↗ |
| TPST Millendo Therapeutics, Inc | A Award | 2021-06-25 | 2021-06-29 | 1,171,094 | — | $0 | 1,171,094 | SEC↗ |
| TPST Millendo Therapeutics, Inc | A Award | 2021-06-25 | 2021-06-29 | 7,377 | — | $0 | 7,377 | SEC↗ |
| ALGS Aligos Therapeutics, Inc. | A Award deriv | 2021-06-17 | 2021-06-17 | 15,000 | — | $0 | 15,000 | SEC↗ |
| ALGS Aligos Therapeutics, Inc. | J Other | 2021-06-11 | 2021-06-15 | 8,383 | — | $0 | 8,383 | SEC↗ |
| ALGS Aligos Therapeutics, Inc. | J Other | 2021-06-11 | 2021-06-15 | 9,719 | — | $0 | 0 | SEC↗ |
| ALGS Aligos Therapeutics, Inc. | J Other | 2021-06-11 | 2021-06-15 | 9,719 | — | $0 | 9,719 | SEC↗ |
| ALGS Aligos Therapeutics, Inc. | J Other | 2021-06-11 | 2021-06-15 | 2,226 | — | $0 | 4,452 | SEC↗ |
| ALGS Aligos Therapeutics, Inc. | J Other | 2021-06-11 | 2021-06-15 | 8,383 | — | $0 | 0 | SEC↗ |
| ALGS Aligos Therapeutics, Inc. | J Other | 2021-06-11 | 2021-06-15 | 485,979 | — | $0 | 1,457,937 | SEC↗ |
| PASG Passage BIO, Inc. | A Award deriv | 2021-05-27 | 2021-05-28 | 16,918 | — | $0 | 16,918 | SEC↗ |
| ADVM Adverum Biotechnologies, I | A Award deriv | 2021-05-12 | 2021-05-14 | 40,000 | — | $0 | 40,000 | SEC↗ |
| ALGS Aligos Therapeutics, Inc. | J Other | 2021-04-26 | 2021-04-28 | 485,979 | — | $0 | 1,943,916 | SEC↗ |
| ALGS Aligos Therapeutics, Inc. | J Other | 2021-04-26 | 2021-04-28 | 9,720 | — | $0 | 9,720 | SEC↗ |
| ALGS Aligos Therapeutics, Inc. | J Other | 2021-04-26 | 2021-04-28 | 9,720 | — | $0 | 0 | SEC↗ |
| ALGS Aligos Therapeutics, Inc. | J Other | 2021-04-26 | 2021-04-28 | 8,385 | — | $0 | 8,385 | SEC↗ |
| ALGS Aligos Therapeutics, Inc. | J Other | 2021-04-26 | 2021-04-28 | 8,385 | — | $0 | 0 | SEC↗ |
| ALGS Aligos Therapeutics, Inc. | J Other | 2021-04-26 | 2021-04-28 | 2,226 | — | $0 | 2,226 | SEC↗ |
| GRTS Gritstone Oncology, Inc. | P Buy | 2020-12-30 | 2021-01-04 | 1,347,709 | $3.71 | $5.00M | 1,347,709 | SEC↗ |
| ADVM Adverum Biotechnologies, I | J Other | 2020-12-14 | 2020-12-16 | 12,783 | — | $0 | 18,822 | SEC↗ |
| ALGS Aligos Therapeutics, Inc. | C Conversion deriv | 2020-10-20 | 2020-10-20 | 198,485 | — | $0 | 0 | SEC↗ |
| ALGS Aligos Therapeutics, Inc. | C Conversion deriv | 2020-10-20 | 2020-10-20 | 85,065 | — | $0 | 0 | SEC↗ |
| ALGS Aligos Therapeutics, Inc. | C Conversion deriv | 2020-10-20 | 2020-10-20 | 463,959 | — | $0 | 0 | SEC↗ |
| ALGS Aligos Therapeutics, Inc. | C Conversion deriv | 2020-10-20 | 2020-10-20 | 2,145,991 | — | $0 | 0 | SEC↗ |
| ALGS Aligos Therapeutics, Inc. | C Conversion deriv | 2020-10-20 | 2020-10-20 | 198,839 | — | $0 | 0 | SEC↗ |
| ALGS Aligos Therapeutics, Inc. | C Conversion | 2020-10-20 | 2020-10-20 | 198,485 | — | $0 | 662,444 | SEC↗ |
| ALGS Aligos Therapeutics, Inc. | P Buy | 2020-10-20 | 2020-10-20 | 200,000 | $15.00 | $3.00M | 862,444 | SEC↗ |
| ALGS Aligos Therapeutics, Inc. | C Conversion | 2020-10-20 | 2020-10-20 | 85,065 | — | $0 | 2,429,895 | SEC↗ |
| ALGS Aligos Therapeutics, Inc. | C Conversion | 2020-10-20 | 2020-10-20 | 2,145,991 | — | $0 | 2,145,991 | SEC↗ |
| ALGS Aligos Therapeutics, Inc. | C Conversion | 2020-10-20 | 2020-10-20 | 198,839 | — | $0 | 2,344,830 | SEC↗ |
| ALGS Aligos Therapeutics, Inc. | C Conversion | 2020-10-20 | 2020-10-20 | 463,959 | — | $0 | 463,959 | SEC↗ |
| ADVM Adverum Biotechnologies, I | A Award deriv | 2020-06-23 | 2020-06-25 | 30,000 | — | $0 | 30,000 | SEC↗ |
| GRTS Gritstone Oncology, Inc. | A Award deriv | 2020-06-18 | 2020-06-22 | 12,500 | — | $0 | 12,500 | SEC↗ |
| PASG Passage BIO, Inc. | C Conversion deriv | 2020-03-03 | 2020-03-03 | 2,977,242 | — | $0 | 0 | SEC↗ |
| PASG Passage BIO, Inc. | C Conversion deriv | 2020-03-03 | 2020-03-03 | 1,049,175 | — | $0 | 0 | SEC↗ |
| PASG Passage BIO, Inc. | C Conversion deriv | 2020-03-03 | 2020-03-03 | 708,352 | — | $0 | 0 | SEC↗ |
| PASG Passage BIO, Inc. | C Conversion deriv | 2020-03-03 | 2020-03-03 | 1,049,175 | — | $0 | 0 | SEC↗ |
| PASG Passage BIO, Inc. | C Conversion deriv | 2020-03-03 | 2020-03-03 | 708,352 | — | $0 | 0 | SEC↗ |
| PASG Passage BIO, Inc. | C Conversion deriv | 2020-03-03 | 2020-03-03 | 2,977,242 | — | $0 | 0 | SEC↗ |
| PASG Passage BIO, Inc. | C Conversion | 2020-03-03 | 2020-03-03 | 2,977,242 | — | $0 | 2,977,242 | SEC↗ |
| PASG Passage BIO, Inc. | C Conversion | 2020-03-03 | 2020-03-03 | 1,049,175 | — | $0 | 4,026,417 | SEC↗ |
| PASG Passage BIO, Inc. | C Conversion | 2020-03-03 | 2020-03-03 | 708,352 | — | $0 | 708,352 | SEC↗ |
| PASG Passage BIO, Inc. | P Buy | 2020-03-03 | 2020-03-03 | 225,000 | $18.00 | $4.05M | 933,352 | SEC↗ |
| PASG Passage BIO, Inc. | C Conversion | 2020-03-03 | 2020-03-03 | 1,049,175 | — | $0 | 4,026,417 | SEC↗ |
| PASG Passage BIO, Inc. | C Conversion | 2020-03-03 | 2020-03-03 | 708,352 | — | $0 | 708,352 | SEC↗ |
| PASG Passage BIO, Inc. | P Buy | 2020-03-03 | 2020-03-03 | 225,000 | $18.00 | $4.05M | 933,352 | SEC↗ |
| PASG Passage BIO, Inc. | C Conversion | 2020-03-03 | 2020-03-03 | 2,977,242 | — | $0 | 2,977,242 | SEC↗ |
| PASG Passage BIO, Inc. | A Award deriv | 2020-02-27 | 2020-03-02 | 33,836 | — | $0 | 33,836 | SEC↗ |
| ADVM Adverum Biotechnologies, I | A Award deriv | 2019-07-31 | 2019-08-02 | 45,000 | — | $0 | 45,000 | SEC↗ |
| GRTS Gritstone Oncology, Inc. | A Award deriv | 2019-06-19 | 2019-06-20 | 8,570 | — | $0 | 8,570 | SEC↗ |
| GRTS Gritstone Oncology, Inc. | C Conversion deriv | 2018-10-02 | 2018-10-02 | 2,173,909 | — | $0 | 0 | SEC↗ |
| GRTS Gritstone Oncology, Inc. | C Conversion deriv | 2018-10-02 | 2018-10-02 | 929,020 | — | $0 | 0 | SEC↗ |
| GRTS Gritstone Oncology, Inc. | C Conversion | 2018-10-02 | 2018-10-02 | 3,102,929 | — | $0 | 3,102,929 | SEC↗ |
| CRSP CRISPR Therapeutics AG | A Award deriv | 2018-06-15 | 2018-06-15 | 30,000 | — | $0 | 30,000 | SEC↗ |
| ADVM Adverum Biotechnologies, I | A Award deriv | 2018-05-31 | 2018-06-15 | 35,000 | — | $0 | 35,000 | SEC↗ |
| CRSP CRISPR Therapeutics AG | S Sale | 2018-05-15 | 2018-05-17 | 1,000 | $58.73 | $58.7K | 640,014 | SEC↗ |
| CRSP CRISPR Therapeutics AG | S Sale | 2018-05-15 | 2018-05-17 | 43,000 | $57.97 | $2.49M | 641,014 | SEC↗ |
| CRSP CRISPR Therapeutics AG | S Sale | 2018-05-08 | 2018-05-09 | 1,653 | $51.45 | $85.0K | 5,629 | SEC↗ |
| CRSP CRISPR Therapeutics AG | S Sale | 2018-05-07 | 2018-05-09 | 3,172 | $50.31 | $159.6K | 39,021 | SEC↗ |
| CRSP CRISPR Therapeutics AG | S Sale | 2018-05-07 | 2018-05-09 | 97,550 | $50.31 | $4.91M | 1,199,784 | SEC↗ |
| CRSP CRISPR Therapeutics AG | S Sale | 2018-05-07 | 2018-05-09 | 2,862 | $50.31 | $144.0K | 35,202 | SEC↗ |
| CRSP CRISPR Therapeutics AG | S Sale | 2018-05-07 | 2018-05-09 | 7,424 | $50.31 | $373.5K | 91,312 | SEC↗ |
| CRSP CRISPR Therapeutics AG | S Sale | 2018-05-07 | 2018-05-09 | 7,645 | $51.26 | $391.9K | 1,192,139 | SEC↗ |
| CRSP CRISPR Therapeutics AG | S Sale | 2018-05-07 | 2018-05-09 | 225 | $51.26 | $11.5K | 34,977 | SEC↗ |
| CRSP CRISPR Therapeutics AG | S Sale | 2018-05-07 | 2018-05-09 | 582 | $51.26 | $29.8K | 90,730 | SEC↗ |
| CRSP CRISPR Therapeutics AG | S Sale | 2018-05-07 | 2018-05-09 | 249 | $51.26 | $12.8K | 38,772 | SEC↗ |
| CRSP CRISPR Therapeutics AG | S Sale | 2018-04-30 | 2018-05-02 | 788 | $50.29 | $39.6K | 38,064 | SEC↗ |
| CRSP CRISPR Therapeutics AG | S Sale | 2018-04-30 | 2018-05-02 | 874 | $50.26 | $43.9K | 42,193 | SEC↗ |
| CRSP CRISPR Therapeutics AG | S Sale | 2018-04-30 | 2018-05-02 | 2,044 | $50.29 | $102.8K | 98,736 | SEC↗ |
| CRSP CRISPR Therapeutics AG | S Sale | 2018-04-30 | 2018-05-02 | 26,860 | $50.29 | $1.35M | 1,297,334 | SEC↗ |
| CRSP CRISPR Therapeutics AG | S Sale | 2018-04-27 | 2018-04-30 | 333 | $50.01 | $16.7K | 43,067 | SEC↗ |
| CRSP CRISPR Therapeutics AG | S Sale | 2018-04-27 | 2018-04-30 | 300 | $50.08 | $15.0K | 38,852 | SEC↗ |
| CRSP CRISPR Therapeutics AG | S Sale | 2018-04-27 | 2018-04-30 | 10,236 | $50.02 | $512.0K | 1,324,194 | SEC↗ |
| CRSP CRISPR Therapeutics AG | S Sale | 2018-04-27 | 2018-04-30 | 779 | $50.03 | $39.0K | 100,780 | SEC↗ |
| CRSP CRISPR Therapeutics AG | S Sale | 2018-04-26 | 2018-04-30 | 14,086 | $50.11 | $705.8K | 101,559 | SEC↗ |
| CRSP CRISPR Therapeutics AG | S Sale | 2018-04-26 | 2018-04-30 | 6,019 | $50.12 | $301.7K | 43,400 | SEC↗ |
| CRSP CRISPR Therapeutics AG | S Sale | 2018-04-26 | 2018-04-30 | 5,430 | $50.12 | $272.2K | 39,152 | SEC↗ |
| CRSP CRISPR Therapeutics AG | S Sale | 2018-04-26 | 2018-04-30 | 185,075 | $50.11 | $9.27M | 1,334,430 | SEC↗ |
| CRSP CRISPR Therapeutics AG | S Sale | 2018-04-24 | 2018-04-26 | 589 | $50.60 | $29.8K | 44,582 | SEC↗ |
| CRSP CRISPR Therapeutics AG | S Sale | 2018-04-24 | 2018-04-26 | 20,071 | $51.00 | $1.02M | 1,519,505 | SEC↗ |
| CRSP CRISPR Therapeutics AG | S Sale | 2018-04-24 | 2018-04-26 | 653 | $51.00 | $33.3K | 49,419 | SEC↗ |
| CRSP CRISPR Therapeutics AG | S Sale | 2018-04-24 | 2018-04-26 | 1,528 | $51.00 | $77.9K | 115,645 | SEC↗ |
| CRSP CRISPR Therapeutics AG | S Sale | 2018-04-23 | 2018-04-24 | 6,821 | $50.66 | $345.6K | 117,173 | SEC↗ |
| CRSP CRISPR Therapeutics AG | S Sale | 2018-04-23 | 2018-04-24 | 89,628 | $50.66 | $4.54M | 1,539,576 | SEC↗ |
| CRSP CRISPR Therapeutics AG | S Sale | 2018-04-23 | 2018-04-24 | 2,630 | $51.00 | $134.1K | 45,171 | SEC↗ |
| CRSP CRISPR Therapeutics AG | S Sale | 2018-04-23 | 2018-04-24 | 2,915 | $51.00 | $148.7K | 50,072 | SEC↗ |
| CRSP CRISPR Therapeutics AG | J Other | 2018-04-20 | 2018-04-24 | 497,053 | — | $0 | 2,238,979 | SEC↗ |
| CRSP CRISPR Therapeutics AG | J Other | 2018-04-20 | 2018-04-24 | 2,947 | — | $0 | 13,277 | SEC↗ |
| CRSP CRISPR Therapeutics AG | J Other | 2018-04-20 | 2018-04-24 | 92,918 | — | $0 | 92,918 | SEC↗ |
| CRSP CRISPR Therapeutics AG | J Other | 2018-04-20 | 2018-04-24 | 92,918 | — | $0 | 0 | SEC↗ |
| CRSP CRISPR Therapeutics AG | J Other | 2018-04-20 | 2018-04-24 | 2,323 | — | $0 | 7,282 | SEC↗ |
| CRSP CRISPR Therapeutics AG | S Sale | 2017-12-22 | 2017-12-27 | 3,059 | $20.29 | $62.1K | 4,959 | SEC↗ |
| CRSP CRISPR Therapeutics AG | S Sale | 2017-11-27 | 2017-11-28 | 200 | $20.24 | $4.0K | 8,018 | SEC↗ |
| CRSP CRISPR Therapeutics AG | S Sale | 2017-11-24 | 2017-11-28 | 1,700 | $20.21 | $34.4K | 8,218 | SEC↗ |
| CRSP CRISPR Therapeutics AG | J Other | 2017-09-05 | 2017-09-07 | 292,529 | — | $0 | 292,529 | SEC↗ |
| CRSP CRISPR Therapeutics AG | J Other | 2017-09-05 | 2017-09-07 | 1,240 | — | $0 | 0 | SEC↗ |
| CRSP CRISPR Therapeutics AG | J Other | 2017-09-05 | 2017-09-07 | 1,240 | — | $0 | 1,240 | SEC↗ |
| CRSP CRISPR Therapeutics AG | J Other | 2017-09-05 | 2017-09-07 | 17,283 | — | $0 | 0 | SEC↗ |
| CRSP CRISPR Therapeutics AG | J Other | 2017-09-05 | 2017-09-07 | 17,283 | — | $0 | 17,283 | SEC↗ |
| CRSP CRISPR Therapeutics AG | J Other | 2017-09-05 | 2017-09-07 | 292,529 | — | $0 | 0 | SEC↗ |
| CRSP CRISPR Therapeutics AG | J Other | 2017-09-05 | 2017-09-07 | 9,918 | — | $0 | 9,918 | SEC↗ |
| CRSP CRISPR Therapeutics AG | J Other | 2017-09-05 | 2017-09-07 | 26,491 | — | $0 | 52,987 | SEC↗ |
| CRSP CRISPR Therapeutics AG | J Other | 2017-09-05 | 2017-09-07 | 61,993 | — | $0 | 123,994 | SEC↗ |
| CRSP CRISPR Therapeutics AG | J Other | 2017-09-05 | 2017-09-07 | 23,899 | — | $0 | 47,801 | SEC↗ |
| CRSP CRISPR Therapeutics AG | J Other | 2017-09-05 | 2017-09-07 | 814,599 | — | $0 | 1,629,204 | SEC↗ |
| CRSP CRISPR Therapeutics AG | J Other | 2017-09-05 | 2017-09-07 | 8,110 | — | $0 | 16,224 | SEC↗ |
| CRSP CRISPR Therapeutics AG | J Other | 2017-09-05 | 2017-09-07 | 1,368,013 | — | $0 | 2,736,032 | SEC↗ |
| ADVM Adverum Biotechnologies, I | A Award deriv | 2017-06-12 | 2017-06-14 | 33,602 | — | $0 | 33,602 | SEC↗ |
| ADVM Adverum Biotechnologies, I | A Award | 2017-06-12 | 2017-06-14 | 22,727 | — | $0 | 70,380 | SEC↗ |
| CRSP CRISPR Therapeutics AG | A Award deriv | 2017-05-31 | 2017-06-02 | 30,000 | — | $0 | 30,000 | SEC↗ |
| ADVM Adverum Biotechnologies, I | A Award | 2017-04-28 | 2017-05-01 | 2,223 | — | $0 | 47,653 | SEC↗ |
| ADVM Adverum Biotechnologies, I | A Award | 2017-03-31 | 2017-04-03 | 3,704 | — | $0 | 45,430 | SEC↗ |
| ADVM Adverum Biotechnologies, I | A Award | 2017-02-28 | 2017-03-02 | 3,774 | — | $0 | 41,726 | SEC↗ |
| ADVM Adverum Biotechnologies, I | A Award | 2017-01-31 | 2017-02-02 | 3,449 | — | $0 | 37,952 | SEC↗ |
| ADVM Adverum Biotechnologies, I | A Award | 2016-12-30 | 2017-01-03 | 3,449 | — | $0 | 34,503 | SEC↗ |
| ADVM Adverum Biotechnologies, I | A Award | 2016-11-30 | 2016-12-01 | 3,509 | — | $0 | 31,054 | SEC↗ |
| ADVM Adverum Biotechnologies, I | A Award | 2016-10-31 | 2016-11-01 | 3,390 | — | $0 | 27,545 | SEC↗ |
| CRSP CRISPR Therapeutics AG | C Conversion deriv | 2016-10-24 | 2016-12-23 | 5,774 | — | $0 | 0 | SEC↗ |
| CRSP CRISPR Therapeutics AG | C Conversion deriv | 2016-10-24 | 2016-12-23 | 2,754 | — | $0 | 0 | SEC↗ |
| CRSP CRISPR Therapeutics AG | C Conversion deriv | 2016-10-24 | 2016-12-23 | 3,100,477 | — | $0 | 0 | SEC↗ |
| CRSP CRISPR Therapeutics AG | C Conversion deriv | 2016-10-24 | 2016-12-23 | 19,524 | — | $0 | 0 | SEC↗ |
| CRSP CRISPR Therapeutics AG | C Conversion deriv | 2016-10-24 | 2016-12-23 | 2,210,417 | — | $0 | 0 | SEC↗ |
| CRSP CRISPR Therapeutics AG | C Conversion deriv | 2016-10-24 | 2016-12-23 | 66,490 | — | $0 | 0 | SEC↗ |
| CRSP CRISPR Therapeutics AG | C Conversion deriv | 2016-10-24 | 2016-12-23 | 168,224 | — | $0 | 0 | SEC↗ |
| CRSP CRISPR Therapeutics AG | C Conversion deriv | 2016-10-24 | 2016-12-23 | 73,704 | — | $0 | 0 | SEC↗ |
| CRSP CRISPR Therapeutics AG | C Conversion deriv | 2016-10-24 | 2016-12-23 | 231,077 | — | $0 | 0 | SEC↗ |
| CRSP CRISPR Therapeutics AG | C Conversion deriv | 2016-10-24 | 2016-12-23 | 1,454 | — | $0 | 0 | SEC↗ |
| CRSP CRISPR Therapeutics AG | C Conversion deriv | 2016-10-24 | 2016-12-23 | 173,167 | — | $0 | 0 | SEC↗ |
| CRSP CRISPR Therapeutics AG | C Conversion deriv | 2016-10-24 | 2016-12-23 | 5,210 | — | $0 | 0 | SEC↗ |
| CRSP CRISPR Therapeutics AG | C Conversion deriv | 2016-10-24 | 2016-12-23 | 13,180 | — | $0 | 0 | SEC↗ |
| CRSP CRISPR Therapeutics AG | C Conversion deriv | 2016-10-24 | 2016-12-23 | 437,247 | — | $0 | 0 | SEC↗ |
| CRSP CRISPR Therapeutics AG | C Conversion | 2016-10-24 | 2016-12-23 | 168,224 | — | $0 | 168,224 | SEC↗ |
| CRSP CRISPR Therapeutics AG | C Conversion | 2016-10-24 | 2016-12-23 | 5,210 | — | $0 | 71,700 | SEC↗ |
| CRSP CRISPR Therapeutics AG | C Conversion | 2016-10-24 | 2016-12-23 | 13,180 | — | $0 | 181,404 | SEC↗ |
| CRSP CRISPR Therapeutics AG | P Buy | 2016-10-24 | 2016-12-23 | 4,583 | $14.00 | $64.2K | 185,987 | SEC↗ |
| CRSP CRISPR Therapeutics AG | C Conversion | 2016-10-24 | 2016-12-23 | 73,704 | — | $0 | 73,704 | SEC↗ |
| CRSP CRISPR Therapeutics AG | C Conversion | 2016-10-24 | 2016-12-23 | 5,774 | — | $0 | 79,478 | SEC↗ |
| CRSP CRISPR Therapeutics AG | C Conversion | 2016-10-24 | 2016-12-23 | 437,247 | — | $0 | 676,895 | SEC↗ |
| CRSP CRISPR Therapeutics AG | C Conversion | 2016-10-24 | 2016-12-23 | 3,100,477 | — | $0 | 3,777,372 | SEC↗ |
| CRSP CRISPR Therapeutics AG | C Conversion | 2016-10-24 | 2016-12-23 | 231,077 | — | $0 | 4,008,449 | SEC↗ |
| CRSP CRISPR Therapeutics AG | P Buy | 2016-10-24 | 2016-12-23 | 95,596 | $14.00 | $1.34M | 4,104,045 | SEC↗ |
| CRSP CRISPR Therapeutics AG | C Conversion | 2016-10-24 | 2016-12-23 | 2,754 | — | $0 | 2,754 | SEC↗ |
| CRSP CRISPR Therapeutics AG | C Conversion | 2016-10-24 | 2016-12-23 | 19,524 | — | $0 | 22,278 | SEC↗ |
| CRSP CRISPR Therapeutics AG | C Conversion | 2016-10-24 | 2016-12-23 | 1,454 | — | $0 | 23,732 | SEC↗ |
| CRSP CRISPR Therapeutics AG | P Buy | 2016-10-24 | 2016-12-23 | 602 | $14.00 | $8.4K | 24,334 | SEC↗ |
| CRSP CRISPR Therapeutics AG | C Conversion | 2016-10-24 | 2016-12-23 | 2,210,417 | — | $0 | 2,210,417 | SEC↗ |
| CRSP CRISPR Therapeutics AG | C Conversion | 2016-10-24 | 2016-12-23 | 173,167 | — | $0 | 2,383,584 | SEC↗ |
| CRSP CRISPR Therapeutics AG | P Buy | 2016-10-24 | 2016-12-23 | 60,219 | $14.00 | $843.1K | 2,443,803 | SEC↗ |
| CRSP CRISPR Therapeutics AG | C Conversion | 2016-10-24 | 2016-12-23 | 66,490 | — | $0 | 66,490 | SEC↗ |
| CRSP CRISPR Therapeutics AG | A Award deriv | 2016-10-18 | 2016-10-20 | 30,000 | — | $0 | 30,000 | SEC↗ |
| CRSP CRISPR Therapeutics AG | A Award deriv | 2016-10-18 | 2016-12-23 | 30,000 | — | $0 | 60,000 | SEC↗ |
| BOLD Audentes Therapeutics, Inc | A Award deriv | 2016-08-24 | 2016-08-25 | 18,000 | — | $0 | 18,000 | SEC↗ |
| BOLD Audentes Therapeutics, Inc | C Conversion deriv | 2016-07-25 | 2016-07-25 | 198,410 | — | $0 | 0 | SEC↗ |
| BOLD Audentes Therapeutics, Inc | C Conversion deriv | 2016-07-25 | 2016-07-25 | 1,081,477 | — | $0 | 0 | SEC↗ |
| BOLD Audentes Therapeutics, Inc | C Conversion deriv | 2016-07-25 | 2016-07-25 | 480,856 | — | $0 | 0 | SEC↗ |
| BOLD Audentes Therapeutics, Inc | C Conversion deriv | 2016-07-25 | 2016-07-25 | 1,249 | — | $0 | 0 | SEC↗ |
| BOLD Audentes Therapeutics, Inc | C Conversion deriv | 2016-07-25 | 2016-07-25 | 3,029 | — | $0 | 0 | SEC↗ |
| BOLD Audentes Therapeutics, Inc | C Conversion deriv | 2016-07-25 | 2016-07-25 | 6,811 | — | $0 | 0 | SEC↗ |
| BOLD Audentes Therapeutics, Inc | C Conversion | 2016-07-25 | 2016-07-25 | 198,410 | — | $0 | 1,760,743 | SEC↗ |
| BOLD Audentes Therapeutics, Inc | P Buy | 2016-07-25 | 2016-07-25 | 219 | $15.00 | $3.3K | 11,308 | SEC↗ |
| BOLD Audentes Therapeutics, Inc | C Conversion | 2016-07-25 | 2016-07-25 | 1,249 | — | $0 | 11,089 | SEC↗ |
| BOLD Audentes Therapeutics, Inc | C Conversion | 2016-07-25 | 2016-07-25 | 3,029 | — | $0 | 9,840 | SEC↗ |
| BOLD Audentes Therapeutics, Inc | C Conversion | 2016-07-25 | 2016-07-25 | 6,811 | — | $0 | 6,811 | SEC↗ |
| BOLD Audentes Therapeutics, Inc | P Buy | 2016-07-25 | 2016-07-25 | 34,781 | $15.00 | $521.7K | 1,795,524 | SEC↗ |
| BOLD Audentes Therapeutics, Inc | C Conversion | 2016-07-25 | 2016-07-25 | 480,856 | — | $0 | 1,562,333 | SEC↗ |
| BOLD Audentes Therapeutics, Inc | C Conversion | 2016-07-25 | 2016-07-25 | 1,081,477 | — | $0 | 1,081,477 | SEC↗ |
| ADVM Adverum Biotechnologies, I | A Award deriv | 2016-05-11 | 2016-07-01 | 44,248 | — | $0 | 44,248 | SEC↗ |
| ADVM Adverum Biotechnologies, I | A Award | 2016-05-11 | 2016-07-01 | 24,155 | — | $0 | 24,155 | SEC↗ |